Document Detail


Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment.
MedLine Citation:
PMID:  20028898     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The purpose of this article is to illustrate the characteristic changes induced in different tumor types by the multitargeted tyrosine kinase inhibitor sorafenib. CONCLUSION: Sorafenib reduces tumor perfusion and thereby induces necrosis and often hemorrhage. Malignant tumors treated with sorafenib undergo both morphologic and functional changes; however, the morphologic changes are less frequent and inadequate for early evaluation of response. Therefore, imaging tools accurately assessing hemorrhage and decrease in tumor perfusion with subsequent necrosis should be the mainstay in monitoring targeted therapy agents.
Authors:
Olga Maksimovic; Christina Schraml; Joerg T Hartmann; Michael Bitzer; Claus D Claussen; Jan Pintoffl; Marius Horger
Related Documents :
14601068 - Near-infrared raman spectroscopy for optical diagnosis of lung cancer.
9243388 - Dynamic mri of a hypovascularized liver tumor model: comparison of a new blood pool con...
22521488 - Pharmacokinetics of a paclitaxel-loaded low molecular weight heparin-all-trans-retinoid...
20385078 - Expression of vacuolar h+-atpases and the intracellular ph values in three adenocarcino...
3141298 - Polyamine-directed preferential nutritional repletion of normal tissues in tumor-bearin...
7524298 - Diffuse embryoma of the testis. an immunohistochemical study of two cases.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  AJR. American journal of roentgenology     Volume:  194     ISSN:  1546-3141     ISO Abbreviation:  AJR Am J Roentgenol     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2009-12-23     Completed Date:  2010-01-26     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7708173     Medline TA:  AJR Am J Roentgenol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  5-14     Citation Subset:  AIM; IM    
Affiliation:
Department of Diagnostic and Interventional Radiology, Eberhard-Karls-University, Hoppe-Seyler-Str. 3, 72076 Tübingen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenal Gland Neoplasms / drug therapy*,  pathology,  radiography,  ultrasonography
Aged
Benzenesulfonates / therapeutic use*
Carcinoma, Hepatocellular / drug therapy*,  pathology,  radiography,  ultrasonography
Carcinoma, Renal Cell / drug therapy*,  pathology,  radiography,  ultrasonography
Contrast Media
Female
Humans
Kidney Neoplasms / drug therapy*,  pathology,  radiography,  ultrasonography
Liver Neoplasms / drug therapy*,  pathology,  radiography,  ultrasonography
Magnetic Resonance Imaging
Male
Middle Aged
Neovascularization, Pathologic / drug therapy*
Pheochromocytoma / drug therapy*,  pathology,  radiography,  ultrasonography
Protein Kinase Inhibitors / therapeutic use*
Pyridines / therapeutic use*
Sensitivity and Specificity
Tomography, X-Ray Computed
Treatment Outcome
Chemical
Reg. No./Substance:
0/Benzenesulfonates; 0/Contrast Media; 0/Protein Kinase Inhibitors; 0/Pyridines; 0/sorafenib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical utility of PET/CT in lymphoma.
Next Document:  Imaging of traumatic brain injury: a review of the recent medical literature.